Characterization of a novelCYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity
- 24 September 2002
- journal article
- research article
- Published by Hindawi Limited in Human Mutation
- Vol. 20 (4) , 275-283
Abstract
The human CYP2A6 enzyme metabolizes certain drugs and pre‐carcinogens and appears to be the most important enzyme for nicotine metabolism. At present, more than 10 different allelic variants are known that cause abolished or decreased enzyme activity. Genetic polymorphism in this gene might be of particular importance for an individual's need for nicotine and for susceptibility to lung and/or liver cancer. We have identified a new CYP2A6 allele (CYP2A6*12) which carries an unequal crossover between the CYP2A6 and CYP2A7 genes in intron 2. This results in a hybrid allele where the 5′ regulatory region and exons 1–2 are of CYP2A7 origin and exons 3–9 are of CYP2A6 origin, resulting in 10 amino acid substitutions compared to the CYP2A6*1 allele. Phenotyping with the CYP2A6 substrate coumarin indicates that it causes reduced CYP2A6 activity in'vivo. Furthermore, when expressed in mammalian COS‐1 cells, the enzyme variant catalyzed 7‐hydroxylation of coumarin at a rate approximately 60% of that of the wild‐type enzyme. The CYP2A6*12 allele was present at an allele frequency of 2.2% among Spaniards, but was absent in Chinese. Hum Mutat 20:275–283, 2002.Keywords
This publication has 32 references indexed in Scilit:
- Polymorphisms of CYP2A6 and its practical consequencesBritish Journal of Clinical Pharmacology, 2001
- CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic ActivityJournal of Biological Chemistry, 2001
- Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolismFEBS Letters, 1999
- The Significance of the Homozygous CYP2A6 Deletion on Nicotine Metabolism: A New Genotyping Method of CYP2A6 Using a Single PCR–RFLPBiochemical and Biophysical Research Communications, 1999
- Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction methodPharmacogenetics, 1999
- DUPLICATION, MULTIDUPLICATION, AND AMPLIFICATION OF GENES ENCODING DRUG-METABOLIZING ENZYMES: EVOLUTIONARY, TOXICOLOGICAL, AND CLINICAL PHARMACOLOGICAL ASPECTSDrug Metabolism Reviews, 1999
- High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation of N‐nitrosodimethylamine and N‐nitrosodiethylamine in mice and humansMolecular Carcinogenesis, 1993
- Interindividual variability of coumarin 7-hydroxylation in healthy volunteersPharmacogenetics, 1992
- The role of individual human cytochrpmes P450 in drug metabolism and clinical responseTrends in Pharmacological Sciences, 1992
- The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomesBiochemistry, 1990